Healthcare [ 10/13 ] | Biotechnology [ 66/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 22, 24 | 0.07 Increased by +110.77% | 0.23 Decreased by -69.57% |
| Nov 9, 23 | 0.3 Increased by +132.61% | 0.44 Decreased by -31.82% |
| Aug 10, 23 | 0.31 Increased by +133.33% | 0.1 Increased by +210% |
| May 11, 23 | 0.02 Increased by +102.15% | -0.24 Increased by +108.33% |
| Mar 13, 23 | -0.65 Increased by +84.34% | -0.82 Increased by +20.73% |
| Nov 10, 22 | -0.92 Increased by +75.85% | -0.97 Increased by +5.15% |
| Aug 11, 22 | -0.93 | -0.87 Decreased by -6.9% |
| May 12, 22 | -0.93 | -0.69 Decreased by -34.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 102.69 M Increased by +29.67 K% | 20.89 M Increased by +138.87% | Increased by +20.35% Increased by +100.13% |
| Jun 30, 23 | 98.22 M Increased by +N/A% | 22.07 M Increased by +140.83% | Increased by +22.47% Decreased by N/A% |
| Mar 31, 23 | 71.43 M Increased by +N/A% | 1.57 M Increased by +103.29% | Increased by +2.2% Decreased by N/A% |
| Dec 31, 22 | 21.89 M Increased by +N/A% | -42.7 M Decreased by -50.66% | Decreased by -195.13% Decreased by N/A% |
| Sep 30, 22 | 345 K Increased by +21.05% | -53.76 M Decreased by -132.29% | Decreased by -15.58 K% Decreased by -91.89% |
| Jun 30, 22 | 0 Decreased by N/A% | -54.07 M Decreased by -146.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -47.85 M Decreased by -229.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -28.34 M Decreased by -229.89% | Decreased by N/A% Decreased by N/A% |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.